Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.110
-0.010 (-0.47%)
May 30, 2025, 4:00 PM - Market closed
Compass Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Compass Therapeutics stock ranges from a low of $5.00 to a high of $32. The average analyst price target of $13.13 forecasts a 522.27% increase in the stock price over the next year.
Price Target: $13.13 (+522.27%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +373.93% | May 9, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +1,416.59% | Apr 28, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +1,037.44% | Apr 21, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +1,416.59% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 850.00K
Revenue Next Year
32.11M
EPS This Year
-0.48
from -0.36
EPS Next Year
-0.56
from -0.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 81.7M | 240.3M | ||
| Avg | n/a | 32.1M | 109.1M | ||
| Low | n/a | 3.7M | 37.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 648.3% | ||
| Avg | - | - | 239.7% | ||
| Low | - | - | 18.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.20 | -0.26 | 0.09 | ||
| Avg | -0.48 | -0.56 | -0.33 | ||
| Low | -0.55 | -0.80 | -0.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.